Activating mutations in FGFR3 have been observed both in the ligand-binding and kinase domains in multiple myelomas, as well as in cancers of the bladder and cervix (L’Hote and Knowles, 2005). This evidence concerns the gene FGFR3 and plasma cell myeloma.